Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO

被引:17
|
作者
Amin, SP
Mullins, CD
Duncan, BS
Blandford, L
机构
[1] Advance Paradigm Clin Serv Inc, Managed Care Pharm, Hunt Valley, MD 21031 USA
[2] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[3] Advance Paradigm Clin Serv Inc, Clin Serv, Hunt Valley, MD 21031 USA
[4] Advance Paradigm Clin Serv Inc, Dis State Management, Hunt Valley, MD 21031 USA
关键词
costs; diabetes mellitus; health care; health maintenance organizations; hospitals; hypertension; pharmacy; institutional; prescriptions;
D O I
10.1093/ajhp/56.15.1515
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The differences in direct health care costs and use between HMO enrollees with both diabetes mellitus and hypertension and enrollees with either disease alone were studied. Two years' worth of medical and pharmacy claims data from a hybrid (independent practice association and group)-model HMO were evaluated. Diagnoses were determined from medical claims data and cross-referenced with prescription information from pharmacy claims data. Aggregate costs associated with each disease, including pharmacy costs, costs of physician office visits, and laboratory costs, were compiled. Comparisons were made of all costs (any cost incurred by the health plan for the member, regardless of disease) and disease-specific costs. The frequency of comorbid conditions was identified. A total of 6195 patients (670 with diabetes and hypertension, 1756 with diabetes alone, and 3769 with hyper tension alone) were assessed. Patients with both diseases incurred much higher costs per year than patients with diabetes or hypertension alone (mean costs, $13,446, $8,493, and $8,424, respectively). Hospitalization costs contributed the greatest amount to total costs, while emergency room costs contributed the least. Disease-specific costs for diabetes and hypertension represented less than one quarter of total health care costs per patient. Average disease-specific costs were highest for patients with both diseases ($2,955), followed by costs for patients with hypertension alone ($1,803) and patients with diabetes alone ($689). The percentage spent on prescriptions was much higher for disease-specific costs than for total costs. The three most common comorbid conditions were dyslipidemia, coronary artery disease, and chronic obstructive pulmonary disease, with the frequency of cerebrovascular disease and myocardial infarction more than double in patients with diabetes and hypertension compared with patients with either disease alone. The cost of care for a patient with both diabetes and hypertension, although not double that for a patient with diabetes or hypertension alone, was higher than the cost of treating either disease.
引用
收藏
页码:1515 / 1520
页数:6
相关论文
共 50 条
  • [1] DIRECT HEALTH CARE COSTS OF DIABETES MELLITUS IN HUNGARY
    Voko, Z.
    Nagyjanosi, L.
    Kalo, Z.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A288 - A288
  • [2] Resource utilization and costs of care of a diabetes management intervention in a group model HMO
    Aubert, RE
    Sikka, R
    Herman, WH
    [J]. DIABETES, 1999, 48 : A420 - A420
  • [3] Analysis of health care costs of patients with diabetes mellitus and hypertension in a public health reference unit in Recife - Brazil
    da Silva Marinho, Michelly Georgia
    Pessoa Cesse, Eduarda Angela
    Benjamin Bezerra, Adriana Falangola
    Carvalho de Sousa, Islandia Maria
    Fontbonne, Annick
    de Carvalho, Eduardo Freese
    [J]. ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2011, 55 (06) : 406 - 411
  • [4] Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus
    Brown, JB
    Nichols, GA
    Glauber, HS
    Bakst, AW
    Schaeffer, M
    Kelleher, CC
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2001, 58 (02) : 151 - 157
  • [5] Patient costs of diabetes mellitus care in public health care facilities in Kenya
    Oyando, Robinson
    Njoroge, Martin
    Nguhiu, Peter
    Sigilai, Antipa
    Kirui, Fredrick
    Mbui, Jane
    Bukania, Zipporah
    Obala, Andrew
    Munge, Kenneth
    Etyang, Anthony
    Barasa, Edwine
    [J]. INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT, 2020, 35 (01): : 290 - 308
  • [6] HMO direct costs and health care resource use after implementation of a monthly limit on sumatriptan
    Goldfarb, SD
    Duncan, BS
    Dans, PE
    Sloan, AS
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (21) : 2206 - 2210
  • [7] Novel Measure of Opioid Dose and Costs of Care for Diabetes Mellitus: Opioid Dose and Health Care Costs
    Gautam, Santosh
    Franzini, Luisa
    Mikhail, Osama I.
    Chan, Wenyaw
    Turner, Barbara J.
    [J]. JOURNAL OF PAIN, 2016, 17 (03): : 319 - 327
  • [8] HEALTH CARE COSTS OF LOSARTAN AND CANDESARTAN IN THE PRIMARY TREATMENT OF HYPERTENSION
    Henriksson, M.
    Russell, D.
    Kjeldsen, S. E.
    Bodegard, J.
    Hasvold, P.
    Levin, L. A.
    [J]. JOURNAL OF HYPERTENSION, 2010, 28 : E240 - E241
  • [9] Direct All-Cause Health Care Costs Associated With Chronic Kidney Disease in Patients With Diabetes and Hypertension: A Managed Care Perspective
    Laliberte, Francois
    Bookhart, Brahim K.
    Vekeman, Francis
    Corral, Mitra
    Duh, Mei Sheng
    Bailey, Robert A.
    Piech, Catherine Tak
    Lefebvre, Patrick
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2009, 15 (04): : 312 - 322
  • [10] Impact of metabolic abnormalities (hypertension, diabetes mellitus, hyperlipidemia) on resource consumption and health care costs in HIV-infected patients
    Lloeje, UH
    Darkow, T
    Tuomari, A
    Fontes, CL
    [J]. VALUE IN HEALTH, 2003, 6 (03) : 266 - 266